SAN DIEGO—Just over a year after approval, AstraZenca’s Calquence is giving Johnson & Johnson and AbbVie’s Imbruvica a run for its money in mantle cell lymphoma. But the British drugmaker doesn’t want ...
Designation based on positive results from two Phase III trials WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca today announced that the US Food and Drug Administration (FDA) has granted Breakthrough ...
WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca’s supplemental New Drug Application (sNDA) for CALQUENCE® (acalabrutinib) has been accepted and granted Priority Review in the US for the treatment of ...
Chasing big fish in the BTK inhibitor market, AstraZeneca’s Calquence was looking for a major sales hook. It may have found just that with new late-stage data in a common form of leukemia. AstraZeneca ...
Fewer patients with chronic lymphocytic leukemia experienced cardiac toxicities with Calquence than those treated with Imbruvica, research showed. Calquence (acalabrutinib) led to fewer ...
There was no major difference in progression-free survival between patients with relapsed/refractory chronic lymphocytic leukemia who were treated with Calquence or Brukinsa. Patients treated with ...
Calquence (acalabrutinib) is a prescription drug used to treat certain cancers of the blood. The drug comes as a tablet that you swallow. It’s usually taken every 12 hours. Calquence is used to treat ...
Calquence (acalabrutinib) is prescribed for specific blood cancers, such as chronic lymphocytic leukemia (CLL). It works by targeting certain cancer cell features to slow their growth. The typical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results